Public float, 1993–2018
In 1999 Stada's German subsidiary, NIDDApharm GmbH, entered the German generic drugs market – worth an estimated 300 million DM.[4]
In September 2000, the company executed a 1:10 share split on the S-MAX.[5] In October the company entered into an agreement with Montenegro Group to acquire the pharmaceutical products of the "Bonomelli Farmacia" product line, rolling into the company's Italian subsidiary, EG S.p.A. – Laboratorie Eurogenerici.[6]
In July 2001 the company acquired the American generic drug supplier MOVA Laboratories Inc.[7]
In April 2002 the company acquired Spanish pharmaceutical company Bayvit S.A from Bayer and Vita S.A. Bayvit is the second-largest supplier of generic drugs in Spain, with recorded sales in 2000 of €20 million.[8] In May, the company acquired Marketing and Sales Operations of the Italian pharmaceutical company Crinos SpA, rolling it into the Italian subsidiary EG SpA.[9] In September the company established a joint venture in Brazil: Ava Stada Pharma Latin America Ltda, 51% owned by Stada and 49% owned by Brazilian company AVA Industrial S/A.[10] In November of the same year, the company acquired an increase shareholding in Ciclum Farma S.A., from 50% to 74%, with Grünenthal GmbH taking over the remaining 26% of shares.[11]
In January, 2003, the company announced its intention to acquire the majority interest in the Italian pharmaceutical company, Pharmajani SpA. Pharmajani specialises in the distribution of pharmacy products, expanding the company's operations and significantly strengthening the distribution capabilities of Stada's Italian subsidiaries, EG SpA and Crinos SpA. The company will change its name to New Pharmajani SpA (NPA).[12] In October the company acquired Schein Pharmaceutical Holdings UK Ltd and its subsidiary Schein Pharmaceutical UK Ltd from Schein Pharmaceutical (Bermuda) Ltd, a subsidiary of US-based Watson Pharmaceuticals, Inc. for €17 million.[13]
In August 2004 the company acquired 97.47%[14] of the shared of Nizhpharm OJSC for between €80.5 million.[15][16]
In April 2005, the company acquired Portuguese generics supplier Ciclum Farma, Unipessoal LDA for €31 million.[17] In May, the company acquired the majority 58% stake in Chinese pharmaceuticals manufacturing company Beijing Center-Lab Pharmaceutical Company Ltd via its subsidiary Stada Pharmaceuticals (Asia) Ltd for €3.5 million. The deal will also strengthen Health Vision Enterprise Ltd, which is 51% owned by the company.[18]
In July 2006, the company sold US subsidiary Stada Inc. to Dava Pharmaceuticals Inc. for $40 million (€31 million).[19] Later in the same month, the company offered to acquire Serbian pharmaceutical group Hemofarm for €485 million (€146.97 per share) – marking Stada's largest acquisition to date.[20]
In August 2007 Stada's Russian subsidiary Nizhpharm OAO, acquired Makiz Group and its associated subsidiaries: Zzo Makiz-Pharma, Zzo Skopinpharm and Zzo Biodyne Pharmaceuticals for €125 million.[21] In the same month the company acquired Forum Bioscience Holdings Ltd for £37.7 million (€55.6 million).[22]
In November 2011, the company acquired the generics division of Spirig Pharma AG[23] for CHF 97 million (€78 million)[24]
In August 2013 the company completed the acquisition of UK-based over-the-counter manufacturer Thornton & Ross for £221.1 million (€259.2 million).[25]
In November 2016 Stada UK Holdings acquired Natures Aid, a manufacturer of vitamins, minerals, food supplements.[26]
